Company: DNLI
Filing Date: 2025-04-17
Form Type: DEF 14A
Source: 0001714899-25-000087
Chunk: 71

Company: Denali Therapeutics Inc.
Filing Date: 2025-04-17
Form: DEF 14A
Chunk 71
---
 regularly scheduled compensation committee meetings, but periodically may be granted by unanimous written consent of the compensation committee.Other grants of stock options approved by the equity award committee are approved in advance, typically on a monthly basis, with the grants effective on the 3 rd of the following month. Grants to our non-employee directors are automatically granted pursuant to our outside director compensation policy. We have never granted stock appreciation rights to any service providers.

Our board of directors, compensation committee, and equity award committee do notconsider material nonpublic information (“MNPI”) when determining the timing or terms of stock options. Further, we have not timedthe release of MNPI for the purpose of affecting the value of executive compensation.

<div align='center'>-53-</div>

On January 8, 2024, three business days after the 2024 annual stock options were granted to our NEOs, the Company issued a press release and furnished a current report on Form 8-K announcing an update on its programs and expected milestones for 2024, as well as the Company’s participation in the 42nd Annual J.P. Morgan Healthcare Conference. The table below sets forth certain information regarding the 2024 annual stock options award to our NEOs. Except for these options, during fiscal year ended December 31, 2024, we did not grant any stock options to any of our NEOs in any period beginning four business days prior to the filing of a periodic report on Form 10‑Q or Form 10‑K or the filing or furnishing of a current report on Form 8‑K that discloses MNPI, and ending one business day after the filing or furnishing of such report.

| Name                      |     | Grant Date |     | Number of securities underlying the award |         |     | Exercise price of the award ($/share) |       |     | Grant date fair value of the award |           |     | Percentage change in the closing market price of the securities underlying the award between the trading day ending immediately prior to the disclosure of material nonpublic information and the trading day beginning immediately following the disclosure of material nonpublic 
 information(1)                                                                                                                                                                                                                                                                     |     |   |
|:--------------------------|:----|:-----------|:----|:------------------------------------------|--------:|:----|:--------------------------------------|------:|:----|:-----------------------------------|----------:|:----|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----:|:--|
| Ryan J. Watts, Ph.D.      |